Details for New Drug Application (NDA): 020120
✉ Email this page to a colleague
NDA 020120 describes ALLERNAZE, which is a drug marketed by Lupin Atlantis and is included in one NDA. Additional details are available on the ALLERNAZE profile page.
The generic ingredient in ALLERNAZE is triamcinolone acetonide. There are fifty-one drug master file entries for this compound. Seventy-three suppliers are listed for this compound. Additional details are available on the triamcinolone acetonide profile page.
The generic ingredient in ALLERNAZE is triamcinolone acetonide. There are fifty-one drug master file entries for this compound. Seventy-three suppliers are listed for this compound. Additional details are available on the triamcinolone acetonide profile page.
Summary for 020120
| Tradename: | ALLERNAZE |
| Applicant: | Lupin Atlantis |
| Ingredient: | triamcinolone acetonide |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 020120
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | SPRAY, METERED;NASAL | Strength | 0.05MG/SPRAY | ||||
| Approval Date: | Feb 4, 2000 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
